Haloperidol

Summary

Haloperidol (CHEMBL54) is an approved small-molecule serotonergic antagonist (ATC N05AD01) targeting HTR7, HTR1A, and DRD1; indicated across 23 conditions including psychotic disorder and tourette syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AD01
• Targets: 14 (HTR7, HTR1A, DRD1…)
• Indications: 23 conditions
• Clinical trials: 126
• Chemistry: 375.9 Da · C21H23ClFNO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL54
Name	Haloperidol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3559
ChEBI	CHEBI:5613
ATC	N05AD01
Molecular formula	C21H23ClFNO2
Molecular weight	375.9
InChIKey	LNEPOXFFQSENCJ-UHFFFAOYSA-N

SMILES: C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F

IUPAC name: 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one

ChEBI definition: A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Pharmacological roles (ChEBI): serotonergic antagonist, first generation antipsychotic, dopaminergic antagonist, antidyskinesia agent, antiemetic.

Also known as: Dolpin, Dozic, Fortunan, Haldol, Haldol solutab, Haloperidol, Haloperidol component of vesalium, Haloperidol decanoate impurity, haloperidol-, Kentace, Keselen, MCN-JR-1625

Parent form; salt/anhydrous children: CHEMBL545608, CHEMBL1160253, CHEMBL2096643, CHEMBL2234294, CHEMBL4297147

Patent coverage: 18,134 distinct patent families (60,883 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR7	5-HT7 receptor	Antagonist	6.6	0.8%	P34969
HTR1A	5-HT1A receptor	Antagonist	5.8	0%	P08908
DRD1	D1 receptor	Antagonist	8.2	0%	P21728
DRD2	D2 receptor	Antagonist	8.8	0%	P14416
DRD3	D3 receptor	Antagonist	8.6	0%	P35462
DRD4	D4 receptor	Antagonist	8.8	0%	P21917
DRD5	D5 receptor	Antagonist	6.3	0%	P21918
HRH1	H1 receptor	Antagonist	6.1	0%	P35367
HTR1D	5-HT1D receptor	Antagonist	6.6	0%	P28221
KCNJ6	Kir3.2	Antagonist	4.1	0.1%	P48051
KCNH1	Kv10.1		6.2	0.2%	O95259
TAS2R10	TAS2R10	Agonist		2.2%	Q9NYW0
HTR2A	5-HT2A receptor	Antagonist	7.3	0%	P28223
HTR2B	5-HT2B receptor	Antagonist	6.4	0.4%	P41595

Broader ChEMBL bioactivity targets: 112 (assay-derived). Sample: Nuclear receptor ROR-gamma, Thrombopoietin, Peripheral myelin protein 22, AP-2 complex subunit sigma, 5-hydroxytryptamine receptor 2B, D(1B) dopamine receptor, Alpha-2A adrenergic receptor, Glutamate receptor ionotropic, NMDA 2B, Muscarinic acetylcholine receptor, Adrenergic receptor alpha-1.

Bioactivity

ChEMBL activities: 937 potent at pChembl ≥ 5 of 964 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD3	10.22	IC50	0.06	nM	CHEMBL_ACT_14996266
P61169	10.12	IC50	0.07	nM	CHEMBL_ACT_688088
DRD2	9.92	Ki	0.12	nM	CHEMBL_ACT_22850778
DRD2	9.92	Ki	0.12	nM	CHEMBL_ACT_946241
DRD2	9.8	IC50	0.16	nM	CHEMBL_ACT_14996282
DRD2	9.8	IC50	0.16	nM	CHEMBL_ACT_19231548
DRD2	9.8	Ki	0.16	nM	CHEMBL_ACT_339467
DRD2	9.8	Ki	0.16	nM	CHEMBL_ACT_420301
SIGMAR1	9.7	Ki	0.2	nM	CHEMBL_ACT_1483734
P61169	9.7	Ki	0.2	nM	CHEMBL_ACT_162079
P61169	9.7	Ki	0.2	nM	CHEMBL_ACT_246567
P61169	9.7	Ki	0.2	nM	CHEMBL_ACT_306788
P61169	9.7	Ki	0.2	nM	CHEMBL_ACT_333463
SIGMAR1	9.68	Ki	0.21	nM	CHEMBL_ACT_18082133
DRD2	9.6	Ki	0.25	nM	CHEMBL_ACT_18204404
DRD3	9.6	IC50	0.25	nM	CHEMBL_ACT_19231542
DRD2	9.58	Ki	0.26	nM	CHEMBL_ACT_23175808
P18901	9.55	IC50	0.28	nM	CHEMBL_ACT_567587
P20288	9.52	Ki	0.3	nM	CHEMBL_ACT_162082
P61169	9.48	Ki	0.33	nM	CHEMBL_ACT_302874
SIGMAR1	9.48	Ki	0.33	nM	CHEMBL_ACT_772380
P61169	9.43	Ki	0.37	nM	CHEMBL_ACT_437594
P61169	9.43	Ki	0.37	nM	CHEMBL_ACT_784829
P18901	9.4	IC50	0.4	nM	CHEMBL_ACT_731994
DRD2	9.38	Ki	0.42	nM	CHEMBL_ACT_18204398
SIGMAR1	9.36	Ki	0.44	nM	CHEMBL_ACT_1278542
DRD2	9.36	Ki	0.44	nM	CHEMBL_ACT_339468
DRD2	9.36	Ki	0.44	nM	CHEMBL_ACT_772378
DRD2	9.33	Ki	0.47	nM	CHEMBL_ACT_19311582
P61169	9.33	Ki	0.47	nM	CHEMBL_ACT_450414

Target pathways

Aggregated over 14 target gene(s): HTR7, HTR1A, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1D, KCNJ6, KCNH1, TAS2R10, HTR2A, HTR2B.

Top Reactome pathways

29 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	6	HTR1A, HTR1D, HTR2A, HTR2B, HTR7, TAS2R10
Signaling by GPCR	6	HTR1A, HTR1D, HTR2A, HTR2B, HTR7, TAS2R10
GPCR ligand binding	6	HTR1A, HTR1D, HTR2A, HTR2B, HTR7, TAS2R10
Class A/1 (Rhodopsin-like receptors)	5	HTR1A, HTR1D, HTR2A, HTR2B, HTR7
Amine ligand-binding receptors	5	HTR1A, HTR1D, HTR2A, HTR2B, HTR7
GPCR downstream signalling	5	HTR1D, HTR2A, HTR2B, HTR7, TAS2R10
Dopamine receptors	5	DRD1, DRD2, DRD3, DRD4, DRD5
Serotonin receptors	5	HTR1A, HTR1D, HTR2A, HTR2B, HTR7
G alpha (i) signalling events	4	DRD3, DRD4, HTR1D, TAS2R10
G alpha (q) signalling events	3	HRH1, HTR2A, HTR2B
G alpha (s) signalling events	3	DRD1, DRD5, HTR7
Neuronal System	2	KCNH1, KCNJ6
Potassium Channels	2	KCNH1, KCNJ6
Neurotransmitter receptors and postsynaptic signal transmission	1	KCNJ6
Transmission across Chemical Synapses	1	KCNJ6
Activation of G protein gated Potassium channels	1	KCNJ6
G protein gated Potassium channels	1	KCNJ6
Inwardly rectifying K+ channels	1	KCNJ6
Voltage gated Potassium channels	1	KCNH1
Histamine receptors	1	HRH1
Class C/3 (Metabotropic glutamate/pheromone receptors)	1	TAS2R10
RHOBTB3 ATPase cycle	1	HTR7
Sensory Perception	1	TAS2R10
Sensory perception of taste	1	TAS2R10
Sensory perception of sweet, bitter, and umami (glutamate) taste	1	TAS2R10
GABA receptor activation	1	KCNJ6
GABA B receptor activation	1	KCNJ6
Activation of GABAB receptors	1	KCNJ6
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits	1	KCNJ6

Dominant GO biological processes

GO term	Targets
signal transduction	12
G protein-coupled receptor signaling pathway	12
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	8
chemical synaptic transmission	8
intracellular calcium ion homeostasis	6
G protein-coupled serotonin receptor signaling pathway	5
response to xenobiotic stimulus	5
behavioral response to cocaine	5
phospholipase C-activating dopamine receptor signaling pathway	5
synaptic transmission, dopaminergic	5
response to cocaine	5
adenylate cyclase-activating G protein-coupled receptor signaling pathway	4
response to amphetamine	4
visual learning	4
smooth muscle contraction	3

Indications & clinical

Indications

23 indications (7 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407
Tourette syndrome	4	MONDO:0007661	EFO:0004895
conduct disorder	4	MONDO:0005352	EFO:0004216
schizoaffective disorder	4	MONDO:0005487	EFO:0005411
mental disorder	4	MONDO:0005084	EFO:0000677
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
delirium	3	MONDO:0045057	EFO:0009267
depressive disorder	3	MONDO:0002050	MONDO:0002050
Alzheimer disease	3	MONDO:0004975	MONDO:0004975
bipolar disorder	3	MONDO:0004985	MONDO:0004985
mood disorder	2	MONDO:0005371	EFO:0004247
methamphetamine dependence	2	MONDO:0005419	EFO:0004701
nicotine dependence	1	MONDO:0008575	EFO:0003768
Huntington disease	1	MONDO:0007739	MONDO:0007739

8 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 126.

Phase distribution

Phase	Trials
PHASE4	43
Not specified	29
PHASE3	28
PHASE2	12
PHASE2/PHASE3	6
PHASE1	6
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06395428	PHASE4	RECRUITING	Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department
NCT07109245	PHASE4	RECRUITING	Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00157378	PHASE4	UNKNOWN	Optimization of Acute Treatment in First Episode Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00191555	PHASE4	COMPLETED	Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment
NCT00253110	PHASE4	COMPLETED	A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
NCT00419653	PHASE4	TERMINATED	Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy
NCT00433121	PHASE4	COMPLETED	Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD
NCT00457366	PHASE4	COMPLETED	A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
NCT00767715	PHASE4	TERMINATED	A Study in the Treatment of Acute Mania
NCT00838032	PHASE4	UNKNOWN	Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia
NCT00859872	PHASE4	COMPLETED	Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia
NCT01052389	PHASE4	COMPLETED	Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia
NCT01157351	PHASE4	COMPLETED	15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
NCT01161277	PHASE4	COMPLETED	Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning
NCT01164059	PHASE4	COMPLETED	Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
NCT01193166	PHASE4	WITHDRAWN	Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital
NCT01530308	PHASE4	COMPLETED	Haloperidol Prophylaxis in Older Emergency Department Patients
NCT01785290	PHASE4	COMPLETED	pRophylactic halopEriDol Use for Delirium in iCu patiEnts With a High Risk for Delirium
NCT02057549	PHASE4	TERMINATED	Haloperidol vs Conventional Therapy for Gastroparesis
NCT02098499	PHASE4	WITHDRAWN	Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the ED: A RCT
NCT02103881	PHASE4	WITHDRAWN	Ketamine Versus Haloperidol for Severe Agitation Outside the Hospital
NCT02199743	PHASE4	COMPLETED	Lurasidone Effects on Tissue Glutamate in Schizophrenia
NCT02213900	PHASE4	COMPLETED	Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
NCT02307396	PHASE4	COMPLETED	Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
NCT02343575	PHASE4	TERMINATED	Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
NCT02380118	PHASE4	TERMINATED	IM Olanzapine Versus Haloperidol or Midazolam
NCT02433041	PHASE4	COMPLETED	Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial
NCT02747511	PHASE4	COMPLETED	IV Haloperidol for the Treatment of Headache in the ED
NCT02909465	PHASE4	COMPLETED	Reducing Ketamine-Induced Agitation, by Midazolam or Haloperidol Premedication After Adult Procedural Sedation
NCT02972502	PHASE4	TERMINATED	Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department
NCT03056482	PHASE4	COMPLETED	Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)
NCT03075657	PHASE4	COMPLETED	Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia
NCT03110900	PHASE4	TERMINATED	Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
NCT03199950	PHASE4	UNKNOWN	PROfylactic Haloperidol in Patients Defined as High Risk for DElirium With Delirium Risk mOdel
NCT03392376	PHASE4	UNKNOWN	Agents Intervening Against Delirium in Intensive Care Unit
NCT03489551	PHASE4	COMPLETED	Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients
NCT03639558	PHASE4	COMPLETED	TREC-Lebanon: A Trial for Rapid Tranquilisation for Agitated Patients in the Emergency Setting

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of DPWG Guideline for haloperidol and CYP2D6	DPWG	CYP2D6	yes	yes

PharmGKB also curates 10 clinical and 65 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

891 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
IMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1
BREXPIPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
Dihydroergotamine	ChEMBL + PubChem	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
CARIPRAZINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
RISPERIDONE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
PENFLURIDOL	ChEMBL	Phase 2	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B, HTR7
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B, HTR7
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B, HTR7
AMOXAPINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B, HTR7
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B, HTR7
DOXEPIN	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B, HTR7
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B, HTR7
KETANSERIN	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
LOXAPINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B, HTR7
MIANSERIN	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
NEFAZODONE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
PROMAZINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B, HTR7
TEGASEROD	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
LYSERGIDE	ChEMBL	Phase 2	DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1D, HTR2A, HTR7
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B
APOMORPHINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B, HTR7
CABERGOLINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B
QUETIAPINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B, HTR7
ROPINIROLE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2B
SILODOSIN	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2B, HTR7
THIORIDAZINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B, HTR7
THIOTHIXENE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B, HTR7
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B, HTR7
RITANSERIN	ChEMBL	Phase 2	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR7
SPIPERONE	ChEMBL	Phase 2	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B, HTR7
SPIRAMIDE	ChEMBL	Phase 2	DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
Pyrazinamide	PubChem	Approved	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B, HTR7
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
Fidaxomicin	ChEMBL + PubChem	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
TAMSULOSIN	ChEMBL + PubChem	Phase 4 (approved)	DRD1, DRD2, DRD3, HRH1, HTR1A, HTR2A, HTR2B, HTR7
ASENAPINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
AZELASTINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, HRH1, HTR1D, HTR2A, HTR2B, HTR7
BENPERIDOL	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
CARVEDILOL	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR7
CINACALCET	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
CISAPRIDE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, HRH1, HTR1A, HTR2A, HTR2B, HTR7
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, HRH1, HTR1A, HTR2A, HTR2B, HTR7
EBASTINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
ILOPERIDONE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
KETOTIFEN	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD5, HRH1, HTR2A, HTR2B, HTR7
LURASIDONE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, HRH1, HTR1A, HTR2A, HTR2B, HTR7
MAPROTILINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD5, HRH1, HTR1A, HTR2A, HTR2B
METHYSERGIDE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, HRH1, HTR1A, HTR2A, HTR2B, HTR7
PERGOLIDE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
PIMOZIDE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
PROMETHAZINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
ROTIGOTINE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B
SALMETEROL	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR1D, HTR2A, HTR2B, HTR7
SERTINDOLE	ChEMBL	Phase 4 (approved)	DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2B